

DAFTAR PUSTAKA

- A.Kambo, G. (2014). Social Movement of Mandar People as a Struggle in Process of Forming West Sulawesi Province. *Journal of Government and Politics*, 5(1), 50–61. <https://doi.org/10.18196/jgp.2014.0005>
- Abbas, A. K., Lichtman, A. H., & Pillai, S. (2018). *Dasar Dasar Immunologi Abbas* (lima). Jakarta.
- Baratawidjaja, K. G., & Rengganis, I. (2018). *Imonologi Dasar* (Edisi 12). Jakarta: Badan Penerbit FKUI.
- Bartsch, E., Medcalf, K. E., Park, A. L., Ray, J. G., Al-Rubaie, Z. T. A., Askie, L. M., ... Van Wagner, V. (2016). Clinical risk factors for pre-eclampsia determined in early pregnancy: Systematic review and meta-analysis of large cohort studies. *BMJ (Online)*, 353. <https://doi.org/10.1136/bmj.i1753>
- Boerrigter, D., Weickert, T. W., Lenroot, R., O'Donnell, M., Galletly, C., Liu, D., ... Weickert, C. S. (2017). Using blood cytokine measures to define high inflammatory biotype of schizophrenia and schizoaffective disorder. *Journal of Neuroinflammation*, 14(1), 1–15. <https://doi.org/10.1186/s12974-017-0962-y>
- Bouthoorn, S. H., Gaillard, R., Steegers, E. A. P., Hofman, A., Jaddoe, V. W. V., Lenthe, F. J. Van, & Raat, H. (2012). *Ethnic Differences in Blood Pressure and Hypertensive*. 198–205. <https://doi.org/10.1161/HYPERTENSIONAHA.112.194365>
- Choe, S., Jun, Y., & Kim, S. (2018). *Exposure to air pollution during preconceptional and prenatal periods and risk of hypertensive disorders of pregnancy : a retrospective cohort study in Seoul , Korea*. 1–10.
- ..., Love, G. D., Karasawa, M., Kawakami, N., Markus, H. R., Tracy, R. P., & ..., C. D. (2012). *have Healthier Profiles than Americans*. 25(3), 494–502. <https://doi.org/10.1016/j.bbi.2010.11.013.Population>



Cornelius, D. C. (2018). Preeclampsia: From inflammation to immunoregulation. *Clinical Medicine Insights: Blood Disorders*, 11.

<https://doi.org/10.1177/1179545X17752325>

Cunningham, F. G., Gant, N. F., Leveno, K. J., Gilstrap, L. C., Hauth, J. C., & Katharine D Wenstrom. (2014). *Obstetri Williams*. Jakarta: EGC.

Didion, S. P. (2017). Cellular and oxidative mechanisms associated with interleukin-6 signaling in the vasculature. *International Journal of Molecular Sciences*, 18(12). <https://doi.org/10.3390/ijms18122563>

Dinkes. (2018). *Profil Dinas Kesehatan Sulawesi Barat*. (Maternal Mortality Rate).

Gan, G. G., Subramaniam, R., Lian, L. H., & Nadarajan, V. S. (2013). Ethnic variation in interleukin-6 -174 (G/C) polymorphism in the Malaysian population. *Balkan Journal of Medical Genetics*, 16(2), 53–58. <https://doi.org/10.2478/bjmg-2013-0032>

Gathiram, P., & Moodley, J. (2016). Pre-eclampsia: Its pathogenesis and pathophysiology. *Cardiovascular Journal of Africa*, 27(2), 71–78. <https://doi.org/10.5830/CVJA-2016-009>

Harmon, A. C., Cornelius, D. C., Amaral, L. M., Faulkner, J. L., Cunningham, M. W., Wallace, K., & Lamarca, B. (2016). The role of inflammation in the pathology of preeclampsia Preeclampsia: Hypertension During Pregnancy. *Clin Sci (Lond)*, 130(6), 409–419. <https://doi.org/10.1042/CS20150702>

Henderson, J., Thompson, J., Burda, B., Cantor, A., Beil, T., & Whitlock, E. (2017). O - Screening for Preeclampsia: A Systematic Evidence Review for the U.S. Preventive Services Task Force. *Agency for Healthcare Research and Quality (US)*, (148). Retrieved from

[//www.ncbi.nlm.nih.gov/books/NBK447462/%0APubMed](https://www.ncbi.nlm.nih.gov/books/NBK447462/%0APubMed)



Ahn, PhD, M., & Al, E. (2017). Racial/ Ethnic disparitie in the association /een preeclampsia risk factors and preeclampsia among women residing in

hawaii. *Physiology & Behavior*, 176(10), 139–148.
<https://doi.org/10.1016/j.physbeh.2017.03.040>

Id, S. S., Kloog, I., Erez, O., Shtein, A., Yitshak-sade, M., Sarov, B., & Novack, L. (2020). *Temperature and preeclampsia : Epidemiological evidence that perturbation in maternal heat homeostasis affects pregnancy outcome*. 38, 1–14. <https://doi.org/10.1371/journal.pone.0232877>

Kemenkes. (2019). *Kemenkes RI Tahun 2015- 2017*. (Idl), 2017–2019.

Kenny, L. C., & Kell, D. B. (2018). Immunological Tolerance Pregnancy, And Preeclampsia: The Role Of Semen Microbes and The Father. *Frontiers in Medicine*, 4(January).

la Marca, B., Brewer, J., & Wallace, K. (2011). IL-6-induced pathophysiology during pre-eclampsia: Potential therapeutic role for magnesium sulfate? *International Journal of Interferon, Cytokine and Mediator Research*, 3(1), 59–64.
<https://doi.org/10.2147/IJICMR.S16320> IL-6-induced

Lin, H., Joehanes, R., Pilling, L. C., Dupuis, J., Lunetta, K. L., Ying, S. X., & Benjamin, E. J. (2011). whole blood gene expression and interleukin-6 levels. *NIH Public Access*, 23(1), 1–7. <https://doi.org/10.1038/jid.2014.371>

Liu, B., Li, Y., Yao, Y., Li, H., Liang, H., Xin, M., ... Liu, S. (2016). Polymorphisms of the IL27 gene in a Chinese Han population complicated with pre-eclampsia. *Scientific Reports*, 6(February), 1–6. <https://doi.org/10.1038/srep23029>

Lockwood, C. J., Yen, C. F., Basar, M., Kayisli, U. A., Martel, M., Buhimschi, I., ... Schatz, F. (2008). Preeclampsia-related inflammatory cytokines regulate interleukin-6 expression in human decidual cells. *American Journal of Pathology*, 172(6), 1571–1579. <https://doi.org/10.2353/ajpath.2008.070629>



α. (1947). *Bugis Makassar, manusia dan kebudayaan*. Makassar: Berita opologi Fakultas Sastra Unhas.

Mrema, D., Lie, R. T., Østbye, T., Mahande, M. J., & Daltveit, A. K. (2018). *The association between pre pregnancy body mass index and risk of preeclampsia : a registry based study from Tanzania.* 1–8.

muhammad Ridwan, A. (2013). *Orang Mandar Orang Laut.* Yogyakarta: Ombak.

Nagakawa, K., Lim, E., Harvey, S., Miyamura, J., & Juarez, D. T. (2017). racial/ethnic disparities in the association between preeclampsia risk factor and preeclampsia among women residing in hawaii. *Physiology & Behavior*, 176(10), 139–148. <https://doi.org/10.1016/j.physbeh.2017.03.040>

Nassar, E. A., Fouda, A. M., & Hassan, K. S. (2019). Influence of low-level laser (LLL) on interleukin 6 (IL-6) levels in gingival crevicular fluid (GCF) during orthodontic tooth movement of periodontally affected rabbits. *International Orthodontics*, 17(2), 227–234. <https://doi.org/10.1016/j.ortho.2019.03.004>

Nguyen, D. P., Genc, M., Vardhana, S., Babula, O., Onderdonk, A., & Witkin, S. S. (2004). Ethnic differences of polymorphisms in cytokine and innate immune system genes in pregnant women. *Obstetrics and Gynecology*, 104(2), 293–300. <https://doi.org/10.1097/01.AOG.0000133486.85400.5e>

Nurul Ilmi, I. (2013). Etnosia. *Journal of Chemical Information and Modeling*, 53(9), 1689–1699. <https://doi.org/10.1017/CBO9781107415324.004>

Palei, A. C., Spradley, F. T., Warrington, J. P., George, E. M., & Granger, J. P. (2013). Pathophysiology of hypertension in pre-eclampsia: A lesson in integrative physiology. *Acta Physiologica*, 208(3), 224–233. <https://doi.org/10.1111/apha.12106>

Perez, A. D., & Hirschman, C. (2010). Population: Emerging American Identities. *National Institute of Health*, 35(1), 1–47. <https://doi.org/10.1111/j.1728-7.2009.00260.x>.The



Verdin-Terán, S. L., Camacho, A., & Moreno-Fierros, L. (2011). Expression of Toll-like Receptor TLR-2, TLR-3, TLR-4 and TLR-9 Is Increased

in Placentas from Patients with Preeclampsia. *Archives of Medical Research*, 42(5), 382–391. <https://doi.org/10.1016/j.arcmed.2011.08.003>

POGI. (2016). *PNPK Diagnosis dan Tatalaksana Preeklampsia*. 1–48.

Pylayeva-Gupta, Y. (2011). The relationship of hypovitaminosis D and IL-6 in preeclampsia. *NIH Public Access*, 23(1), 1–7. <https://doi.org/10.1038/jid.2014.371>

Raghupathy, R. (2013). Cytokines as key players in the pathophysiology of preeclampsia. *Medical Principles and Practice*, 22(SUPPL.1), 8–19. <https://doi.org/10.1159/000354200>

Rahayu, W. (2017). *Suku Toraja, Sulawesi*. Retrieved from <http://protomalayans.blogspot.co.at/2012/10/suku-toraja-sulawesi.html>

Saito, S., & Sakai, M. (2003). Th1/Th2 balance in preeclampsia. *Journal of Reproductive Immunology*, 59(2), 161–173. [https://doi.org/10.1016/S0165-0378\(03\)00045-7](https://doi.org/10.1016/S0165-0378(03)00045-7)

Sankaralingam, S., Arenas, I. A., Lalu, M. M., & Davidge, S. T. (2006). Preeclampsia: Current understanding of the molecular basis of vascular dysfunction. *Expert Reviews in Molecular Medicine*, 8(3), 1–20. <https://doi.org/10.1017/S1462399406010465>

Shah, D. A., & Khalil, R. A. (2015). Bioactive factors in uteroplacental and systemic circulation link placental ischemia to generalized vascular dysfunction in hypertensive pregnancy and preeclampsia. *Biochemical Pharmacology*, 95(4), 211–226. <https://doi.org/10.1016/j.bcp.2015.04.012>

Shental, O., Friger, M., & Sheiner, E. (2010). Ethnic differences in the monthly variation of preeclampsia among Bedouin and Jewish parturients in the Negev. *Hypertension in Pregnancy*, 29(3), 342–349. <https://doi.org/10.3109/10641950902968692>



Siemieniuch, M. J., Szóstek, A. Z., Gajos, K., Kozdrowski, R., Nowak, M., & Okuda, K. (2016). Type of inflammation differentially affects expression of interleukin 1 β and 6, tumor necrosis factor- α and toll-like receptors in subclinical endometritis in mares. *PLoS ONE*, 11(5). <https://doi.org/10.1371/journal.pone.0154934>

Subowo. (2014). *Imunobiologi*. Jakarta: Sagung Seto.

Taimoor, A., Buland, K., Nazir, A., & Qureshi, S. A. (2019). *comparison of serum homocysteine levels in primigravidas during second and third trimesters of normal pregnancy and preeclampsia*. 69(2), 302–307.

Taylor, B. D., & Al, E. (2017). *mid-pregnancy Circulating immune Biomarkers in women with Preeclampsia and Normotensive Controls*. 25(5), 1032–1057. <https://doi.org/10.1111/mec.13536>.Application

Udenze, I., Amadi, C., Awolola, N., & Makwe, C. C. (2015). The role of cytokines as inflammatory mediators in preeclampsia. *Pan African Medical Journal*, 20, 1–6. <https://doi.org/10.11604/pamj.2015.20.219.5317>

USU, O. (2018). *Pertemuan Ilmiah Tahunan Fetomaternal 19*.

Valencia-Ortega, J., Zárate, A., Saucedo, R., Hernández-Valencia, M., Cruz, J. G., & Puello, E. (2019). Placental Proinflammatory State and Maternal Endothelial Dysfunction in Preeclampsia. *Gynecologic and Obstetric Investigation*, 84(1), 12–19. <https://doi.org/10.1159/000491087>

Valencia Villalvazo, E. Y., Canto-Cetina, T., Romero Arauz, J. F., Coral-Vázquez, R. M., Canizales-Quinteros, S., Coronel, A., ... Canto, P. (2012). Analysis of polymorphisms in interleukin-10, interleukin-6, and interleukin-1 receptor antagonist in Mexican-Mestizo women with pre-eclampsia. *Genetic Testing and Molecular Biomarkers*, 16(11), 1263–1269.

[s://doi.org/10.1089/gtmb.2012.0181](https://doi.org/10.1089/gtmb.2012.0181)



., & Miskad, U. A. (2017). *Imunologi Lebih Mudah Difahami*. Surabaya: an Internasional.

Webster, L. M., Gill, C., Seed, P. T., Bramham, K., Wiesender, C., Nelson-Piercy, C., ... Chappell, L. C. (2018). Chronic hypertension in pregnancy: Impact of ethnicity and superimposed preeclampsia on placental, endothelial, and renal biomarkers. *American Journal of Physiology - Regulatory Integrative and Comparative Physiology*, 315(1), R36-R47,.
<https://doi.org/10.1152/ajpregu.00139.2017>

WHO. (2017). *Kemendes RI Tahun 2015- 2017*. (Idl), 2017–2019.

Wijaya, H. (2018). Mengenal Budaya Suku Bugis (Pendekatan Misi Terhadap Suku Bugis). *Jurnal Lembaga STAKN Kupang*, 6(2), 153–173.

Yuniarti, E., Putri, D. H., Yuni, S., Puja, A., Sonata, D., Biologi, J., & Padang, U. N. (2018). *CORRELATION OF FASTING BLOOD GLUCOSE WITH IL-6*. 2(1), 11–21. <https://doi.org/10.24036/02018219858-0-00>

Zhang, M., Xu, J., Bao, X., Niu, W., Wang, L., Du, L., ... Sun, Y. (2017). Association between genetic polymorphisms in interleukin genes and recurrent pregnancy loss - A systematic review and meta-analysis. *PLoS ONE*, 12(1), 1–17.
<https://doi.org/10.1371/journal.pone.0169891>



Lampiran 2.

**FORMULIR PENGAMBILAN DATA PENELITIAN ANALISIS KADAR IL-6 PADA
IBU HAMIL TRIMESTER III DENGAN PREEKLAMPSIA DAN NORMOTENSI
DISUKU BUGIS, MAKASSAR, MANDAR DAN TORAJA**

1. UMUM

Nama Pasien :

Nama Suami :

Alamat :

Kel / Kec :

Wilayah :

Telepon (No. HP) :

2. REGISTRASI

RS / PKM :

No. ID Pasien :

Tgl Pemeriksaan :

3. ANAMNESIS

Umur :

Pendidikan :

Pekerjaan :

Paritas : G P A

HPHT :

Gestasi :

Riwayat Penyakit Terdahulu (Sampel di eksklusi bila menderita)

Hipertensi Lain-lain (sebutkan):

antung

iabetes Melitus

injal



Riwayat Kehamilan yang lalu :

Penyakit	Ya / Tidak (*)	Keterangan (Bila Perlu)
Preeklamsia	Ya / Tidak	
Hipertensi Dalam Kehamilan	Ya / Tidak	
IUGR / PJT	Ya / Tidak	
KJDR	Ya / Tidak	
Lain-lain (sebutkan)	

* Coret yang tidak perlu

Riwayat Penyakit Sekarang :

- Antenatal Care Sebelumnya : Bidan / Puskesmas / Dokter / Rumah Sakit
- ANC Teratur / Tidak (sebutkan frekuensi.....)
- Tekanan Darah Meningkat Sejak Umur Kehamilan mgg (bila diketahui)
- Disertai sakit kepala berat / nyeri ulu hati / ggn penglihatan **(Ya / Tidak)***
- Perut Tegang **(Ya / Tidak)***
- Perdarahan dari jalan lahir **(Ya / Tidak)***

Riwayat Perkawinan (diisi bila sampel menikah lebih dari sekali atau isteri kedua)

- Kehamilan ini dari perkawinan ke
- Pada Pernikahan sebelumnya pernah preeclampsia **(Ya / Tidak)***
- Pada Isteri lain dari suami menderita preeclampsia **(Ya / Tidak)***

4. PEMERIKSAAN FISIK

Keadaan Umum :

Kesadaran :

Tekanan Darah : mmHg

Tinggi Badan : cm

Berat sebelum Hamil : kg

Berat sekarang : kg

Glukosa : - / +



5. HASIL PEMERIKSAAN LABORATORIUM

Protein Urine :

6. IDENTIFIKASI SUKU

Suku : Bugis / Makassar / Mandar / Toraja

Bahasa Rumah :

Tempat Lahir :


Petunjuk Pengisian Genogram:



: Suku Campuran (*Multi Tribes*)



: Suku Asli (*Single Tribe*)



Lampiran 3

SURAT PERMOHONAN MENJADI RESPONDEN

Makassar, November 2019

Dengan hormat,

Saya yang bertanda tangan dibawah ini mahasiswi S2 Ilmu Kebidanan di Universitas Hasanuddin Makassar

Nama : Eka Fitri Amir

Nim : P102181019

Alamat : Jl.Tamangapa Raya III, Perum Surya Asri Blok D No 9

Akan mengadakan penelitian dengan judul “Perbedaan Kadar *Interleukin-6* (IL-6) Pada Ibu Hamil Trimester III dengan Preeklamsia di Suku Bugis, Makassar, Mandar, dan Toraja”.

Dalam penelitian ini ibu akan mendapatkan pemeriksaan kehamilan selanjutnya peneliti akan mengambil darah ibu menggunakan spoit sebanyak 3 cc untuk dilakukan pemeriksaan laboratorium Rumah Sakit Pendidikan Universitas Hasanuddin.

Penelitian ini tidak akan menimbulkan akibat yang merugikan bagi responden dan kerahasiaan identitas dan data akan dijaga dengan baik, untuk itu saya mohon kesediaan ibu untuk berpartisipasi dalam mengisi lembar pernyataan yang diberikan. Jika ibu tidak bersedia untuk menjadi dalam penelitian ini maka ibu berhak untuk mengundurkan diri.

Hormat saya,

Eka Fitri Amir



Lampiran 4

LEMBAR KESEDIAAN MENJADI RESPONDEN

Saya yang bertanda tangan dibawah ini:

Nama :

Umur :

Alamat :

Menyatakan bersedia menjadi responden pada penelitian yang akan dilakukan oleh Eka Fitri Amir, mahasiswi S2 Ilmu Kebidanan di Unversitas Hasanuddin Makassar yang berjudul: Perbedaan Kadar *Interleukin-6* (IL-6) Pada Ibu Hamil Trimester III dengan Preeklamsia di Suku Bugis, Makassar, Mandar, dan Toraja”.

Saya memahami bahwa penelitian ini tidak akan menimbulkan akibat buruk, oleh karena itu saya bersedia menjadi reponden.

, November
2019

Reponden

()





KEMENTERIAN PENDIDIKAN DAN KEBUDAYAAN
UNIVERSITAS HASANUDDIN FAKULTAS KEDOKTERAN
KOMITE ETIK PENELITIAN KESEHATAN
RSPTN UNIVERSITAS HASANUDDIN
RSUP Dr. WAHIDIN SUDIROHUSODO MAKASSAR
Sekretariat : Lantai 2 Gedung Laboratorium Terpadu
JL.PERINTIS KEMERDEKAAN KAMPUS TAMALANREA KM.10 MAKASSAR 90245.



Contact Person: dr. Agussalim Bukhari.,MMed.PhD.,SpGK TELP. 081241850858, 0411 5780103. Fax : 0411-581431

REKOMENDASI PERSETUJUAN ETIK

Nomor : 106/UN4.6.4.5.31/ PP36/ 2020

Tanggal: 3 Februari 2020

Dengan ini Menyatakan bahwa Protokol dan Dokumen yang Berhubungan Dengan Protokol berikut ini telah mendapatkan Persetujuan Etik :

No Protokol	UH19121049	No Sponsor	
Peneliti Utama	Eka Fitri Amir, SST	Sponsor	
Judul Peneliti	Analisis Perbedaan Kadar IL-6 Pada Ibu Hamil Preeklamsia di Suku Bugis, Makassar, Mandar dan Toraja		
No Versi Protokol	2	Tanggal Versi	30 Januari 2020
No Versi PSP	2	Tanggal Versi	30 Januari 2020
Tempat Penelitian	RSIA Pertiwi, RSIA Siti Fatimah, Puskesmas Bara-Barayya, RSUD Daya, Puskesmas Kassi Kassi, RSIA St. Khadijah, RSIA Ananda Makassar, RSUD & Puskesmas di Kota Pinrang, RSUD dan Puskesmas Kota Majene, RS Dan PKM di Tana Toraja		
Jenis Review	<input type="checkbox"/> Exempted <input checked="" type="checkbox"/> Expedited <input type="checkbox"/> Fullboard Tanggal	Masa Berlaku 3 Februari 2020 sampai 3 Februari 2021	Frekuensi review lanjutan
Ketua Komisi Etik Penelitian Kesehatan FKUH	Nama Prof.Dr.dr. Suryani As'ad, M.Sc.,Sp.GK (K)	Tanda tangan	
Sekretaris Komisi Etik Penelitian Kesehatan FKUH	Nama dr. Agussalim Bukhari, M.Med.,Ph.D.,Sp.GK (K)	Tanda tangan	

Kewajiban Peneliti Utama:

- Menyerahkan Amandemen Protokol untuk persetujuan sebelum di implementasikan
- Menyerahkan Laporan SAE ke Komisi Etik dalam 24 Jam dan dilengkapi dalam 7 hari dan Laporan SUSAR dalam 72 Jam setelah Peneliti Utama menerima laporan
- Menyerahkan Laporan Kemajuan (progress report) setiap 6 bulan untuk penelitian resiko tinggi dan setiap setahun untuk penelitian resiko rendah
- Menyerahkan laporan akhir setelah Penelitian berakhir
- Melaporkan penyimpangan dari protokol yang disetujui (protocol deviation / violation)
- Mematuhi semua peraturan yang ditentukan



Optimized using
trial version
www.balesio.com



PEMERINTAH KABUPATEN PINRANG
RUMAH SAKIT UMUM DAERAH LASINRANG

Jl. Macan No. 22 Telp. (0421)921 298 - 924 776 Fax (0421)924 776 Pinrang 91212



SURAT IZIN PENELITIAN

NOMOR : 004/RSUL/DIKLAT/III/2020

Kepada Yth:

1. Kepala Ruang
2. Kepala Bagian Rekam Medik

Di

Tempat

Dengan Hormat,

Memenuhi Surat Universitas Hasanuddin Makassar Nomor :
1384/UN4.20.1/PT.01.04/2020 tertanggal 09 Maret 2020, diharapkan kesediaan saudara(i) untuk
memberikan informasi / data yang diperlukan kepada :

N a m a : **EKA FITRI AMIR**
N I M : P102181019
Program Studi : S2 Kebidanan Unhas Makassar
Alamat : Alupang Desa Padakkalawa Kab. Pinrang

Penelitian ini akan dilaksanakan pada tanggal 17 Maret s/d 17 Mei 2020 dengan judul
**"ANALISIS PERBEDAAN KADAR IL-6 PADA IBU HAMIL PREEKLAMSI DI SUKU
BUGIS, MAKASSAR, MANDAR DAN TORAJA"**.

Demikian di sampaikan, atas kerjasama yang baik di ucapkan banyak terima kasih.

Pinrang, 17 Maret 2020

An. Direktur RSUD Lasinrang.

Ka Sub.Bid Pengembangan

SDM dan Remunerasi



Mahyuddin, SKM

NIP. 19671013 198803 1 005



Kruskal-Wallis Test responden Normotensi

Descriptives

	SUKU		Statistic	Std. Error		
KADAR IL-6	MAKASSAR	Mean	81.9164	11.57294		
		95% Confidence Interval for Mean	Lower Bound 56.1302 Upper Bound 107.7025			
		5% Trimmed Mean	83.2093			
		Median	98.1200			
		Variance	1473.263			
		Std. Deviation	38.38311			
		Minimum	19.12			
		Maximum	121.44			
		Range	102.32			
		Interquartile Range	77.11			
		Skewness	-.829	.661		
		Kurtosis	-.921	1.279		
		BUGIS		Mean	81.9209	6.29268
				95% Confidence Interval for Mean	Lower Bound 67.9000 Upper Bound 95.9419	
5% Trimmed Mean	82.2643					
Median	80.1000					
Variance	435.575					
Std. Deviation	20.87045					
Minimum	45.54					
Maximum	112.12					
Range	66.58					
Interquartile Range	28.80					
Skewness	-.151			.661		
Kurtosis	-.331			1.279		
MANDAR				Mean	67.2845	5.36890
				95% Confidence Interval for Mean	Lower Bound 55.3219 Upper Bound 79.2472	
		5% Trimmed Mean	67.9534			
		Median	70.1200			



	Variance		317.076	
	Std. Deviation		17.80663	
	Minimum		35.12	
	Maximum		87.41	
	Range		52.29	
	Interquartile Range		33.21	
	Skewness		-.580	.661
	Kurtosis		-.913	1.279
TORAJA	Mean		55.5282	7.21416
	95% Confidence Interval for Mean	Lower Bound	39.4540	
		Upper Bound	71.6023	
	5% Trimmed Mean		54.8174	
	Median		54.8600	
	Variance		572.486	
	Std. Deviation		23.92667	
	Minimum		25.12	
	Maximum		98.73	
	Range		73.61	
	Interquartile Range		38.52	
	Skewness		.534	.661
	Kurtosis		-.665	1.279

Tests of Normality

	SUKU	Kolmogorov-Smirnov ^a			Shapiro-Wilk		
		Statistic	Df	Sig.	Statistic	df	Sig.
KADAR IL-6	MAKASSAR	.223	11	.133	.833	11	.026
	BUGIS	.152	11	.200*	.954	11	.694
	MANDAR	.120	11	.200*	.981	11	.971
	TORAJA	.190	11	.200*	.946	11	.594

*. This is a lower bound of the true significance.

Significance Correction



Test of Homogeneity of Variance

		Levene Statistic	df1	df2	Sig.
KADAR IL-6	Based on Mean	2.444	3	40	.078
	Based on Median	1.239	3	40	.308
	Based on Median and with adjusted df	1.239	3	22.864	.318
	Based on trimmed mean	2.261	3	40	.096

NPar Tests

Descriptive Statistics

	N	Mean	Std. Deviation	Minimum	Maximum
KADAR IL-6	44	79.3898	31.34196	19.12	127.45
SUKU	44	2.50	1.131	1	4

Ranks

	SUKU	N	Mean Rank
KADAR IL-6	MAKASSAR	11	24.00
	BUGIS	11	32.55
	MANDAR	11	22.00
	TORAJA	11	11.45
	Total	44	

Test Statistics^{a,b}

	KADAR IL-6
Chi-Square	15.029
df	3
Asymp. Sig.	.002

a. Kruskal Wallis Test

b. Grouping Variable: SUKU



Mann-Whitney Test (post hock normotensi)

Ranks

	SUKU	N	Mean Rank	Sum of Ranks
KADAR IL-6	MAKASSAR	11	9.55	105.00
	BUGIS	11	13.45	148.00
	Total	22		

Test Statistics^a

	KADAR IL-6
Mann-Whitney U	39.000
Wilcoxon W	105.000
Z	-1.412
Asymp. Sig. (2-tailed)	.158
Exact Sig. [2*(1-tailed Sig.)]	.171 ^b

a. Grouping Variable: SUKU

b. Not corrected for ties.

Ranks

	SUKU	N	Mean Rank	Sum of Ranks
KADAR IL-6	MAKASSAR	11	12.27	135.00
	MANDAR	11	10.73	118.00
	Total	22		

Test Statistics^a

	KADAR IL-6
Mann-Whitney U	52.000
Wilcoxon W	118.000
Z	-.558
Asymp. Sig. (2-tailed)	.577
Exact Sig. [2*(1-tailed Sig.)]	.606 ^b

a. Grouping Variable: SUKU

b. Not corrected for ties.



3TS

Ranks

	SUKU	N	Mean Rank	Sum of Ranks
KADAR IL-6	MAKASSAR	11	14.18	156.00
	TORAJA	11	8.82	97.00
	Total	22		

Test Statistics^a

	KADAR IL-6
Mann-Whitney U	31.000
Wilcoxon W	97.000
Z	-1.938
Asymp. Sig. (2-tailed)	.053
Exact Sig. [2*(1-tailed Sig.)]	.056 ^b

a. Grouping Variable: SUKU

b. Not corrected for ties.

Responden Preeklamsia

Descriptives

	SUKU	Statistic	Std. Error
KADAR IL-6	MAKASSAR	Mean	144.5436
		95% Confidence Interval for Mean	18.27209
		Lower Bound	103.8309
		Upper Bound	185.2564
		5% Trimmed Mean	142.3213
		Median	121.5300
		Variance	3672.563
		Std. Deviation	60.60167
		Minimum	78.98
		Maximum	250.11
		Range	171.13
		Interquartile Range	121.01
		Skewness	.771
	Kurtosis	-.868	1.279
BUGIS		Mean	98.7018
		95% Confidence Interval for Mean	6.52892
		Lower Bound	84.1545
	Upper Bound	113.2492	



	5% Trimmed Mean		97.5598	
	Median		90.7700	
	Variance		468.895	
	Std. Deviation		21.65398	
	Minimum		74.73	
	Maximum		143.23	
	Range		68.50	
	Interquartile Range		38.63	
	Skewness		.908	.661
	Kurtosis		.004	1.279
MANDAR	Mean		93.8673	5.18191
	95% Confidence Interval for Mean	Lower Bound	82.3213	
		Upper Bound	105.4133	
	5% Trimmed Mean		94.1759	
	Median		97.1200	
	Variance		295.374	
	Std. Deviation		17.18645	
	Minimum		61.64	
	Maximum		120.54	
	Range		58.90	
	Interquartile Range		27.72	
	Skewness		-.225	.661
	Kurtosis		-.197	1.279
TORAJA	Mean		111.7691	20.64951
	95% Confidence Interval for Mean	Lower Bound	65.7591	
		Upper Bound	157.7791	
	5% Trimmed Mean		109.9268	
	Median		75.3400	
	Variance		4690.426	
	Std. Deviation		68.48668	
	Minimum		45.58	
	Maximum		211.12	
	Range		165.54	
	Interquartile Range		147.10	
	Skewness		.668	.661



Kurtosis	-1.532	1.279
----------	--------	-------

Tests of Normality

	SUKU	Kolmogorov-Smirnov ^a			Shapiro-Wilk		
		Statistic	df	Sig.	Statistic	df	Sig.
KADAR IL-6	MAKASSAR	.204	11	.200*	.870	11	.077
	BUGIS	.148	11	.200*	.922	11	.337
	MANDAR	.178	11	.200*	.900	11	.185
	TORAJA	.191	11	.200*	.855	11	.049

*. This is a lower bound of the true significance.

a. Lilliefors Significance Correction

KADAR IL-6

Descriptive Statistics

	N	Mean	Std. Deviation	Minimum	Maximum
KADAR IL-6	44	120.2914	48.52324	45.58	250.11
SUKU	44	2.50	1.131	1	4

Kruskal-Wallis Test

Ranks

	SUKU	N	Mean Rank
KADAR IL-6	MAKASSAR	11	31.36
	BUGIS	11	23.36
	MANDAR	11	16.00
	TORAJA	11	19.27
	Total	44	

Test Statistics^{a,b}

	KADAR IL-6
Chi-Square	8.798
df	3
g.	.032

Wallis Test

g Variable: SUKU



Mann whitney Post Hoc Preeklamsia

Ranks

	SUKU	N	Mean Rank	Sum of Ranks
KADAR IL-6	MAKASSAR	11	13.73	151.00
	BUGIS	11	9.27	102.00
	Total	22		

Test Statistics^a

	KADAR IL-6
Mann-Whitney U	36.000
Wilcoxon W	102.000
Z	-1.609
Asymp. Sig. (2-tailed)	.108
Exact Sig. [2*(1-tailed Sig.)]	.116 ^b

a. Grouping Variable: SUKU

b. Not corrected for ties.

	SUKU	N	Mean Rank	Sum of Ranks
KADAR IL-6	MAKASSAR	11	15.73	173.00
	MANDAR	11	7.27	80.00
	Total	22		

Test Statistics^a

	KADAR IL-6
Mann-Whitney U	14.000
Wilcoxon W	80.000
Z	-3.053
Asymp. Sig. (2-tailed)	.002
Exact Sig. [2*(1-tailed Sig.)]	.001 ^b

a. Grouping Variable: SUKU

b. Not corrected for ties.



Ranks

	SUKU	N	Mean Rank	Sum of Ranks
KADAR IL-6	MAKASSAR	11	13.91	153.00
	TORAJA	11	9.09	100.00
	Total	22		

Test Statistics^a

	KADAR IL-6
Mann-Whitney U	34.000
Wilcoxon W	100.000
Z	-1.740
Asymp. Sig. (2-tailed)	.082
Exact Sig. [2*(1-tailed Sig.)]	.088 ^b

a. Grouping Variable: SUKU

b. Not corrected for ties.

Mann-Whitney Test

Ranks

SUKU	STATUS PRE EKLAMPSIA	N	Mean Rank	Sum of Ranks
MAKASSAR	KADAR IL-6 PREEKLAMPSIA	11	15.91	175.00
	NORMOTENSI	11	7.09	78.00
	Total	22		
BUGIS	KADAR IL-6 PREEKLAMPSIA	11	12.82	141.00
	NORMOTENSI	11	10.18	112.00
	Total	22		
MANDAR	KADAR IL-6 PREEKLAMPSIA	11	14.00	154.00
	NORMOTENSI	11	9.00	99.00
	Total	22		
TORAJA	KADAR IL-6 PREEKLAMPSIA	11	15.00	165.00
	NORMOTENSI	11	8.00	88.00
	Total	22		



Test Statistics^a



SUKU		KADAR IL-6
MAKASSAR	Mann-Whitney U	12.000
	Wilcoxon W	78.000
	Z	-3.185
	Asymp. Sig. (2-tailed)	.001
	Exact Sig. [2*(1-tailed Sig.)]	.001 ^b
BUGIS	Mann-Whitney U	46.000
	Wilcoxon W	112.000
	Z	-.952
	Asymp. Sig. (2-tailed)	.341
	Exact Sig. [2*(1-tailed Sig.)]	.365 ^b
MANDAR	Mann-Whitney U	33.000
	Wilcoxon W	99.000
	Z	-1.806
	Asymp. Sig. (2-tailed)	.071
	Exact Sig. [2*(1-tailed Sig.)]	.076 ^b
TORAJA	Mann-Whitney U	22.000
	Wilcoxon W	88.000
	Z	-2.529
	Asymp. Sig. (2-tailed)	.011
	Exact Sig. [2*(1-tailed Sig.)]	.010 ^b

a. Grouping Variable: STATUS PRE EKLAMPSIA

b. Not corrected for ties.



Dokumentasi Penelitian



Optimized using
trial version
www.balesio.com